| |
| Issue |
Title |
| |
| No 1 (2021): Comorbid States (1) |
Stroke and COVID‑19 |
Abstract
PDF (Rus)
|
|
T. M. Ostroumova, O. D. Ostroumova, N. A. Arablinsky, O. V. Golovina |
| |
| No 1 (2021): Comorbid States (1) |
Antibiotic‑associated drug‑induced liver damage with cholestasis: actualization of problem in COVID‑19 era |
Abstract
PDF (Rus)
|
|
O. D. Ostroumova, A. P. Pereverzev, E. E. Pavleeva, R. R. Romanovsky |
| |
| No 1 (2021): Comorbid States (1) |
Levels of high‑sensitivity C‑reactive protein in young and middle‑aged individuals and their association with hypertension |
Abstract
PDF (Rus)
|
|
O. A. Polyakova, A. A. Kirichenko, I. A. Borodin |
| |
| No 1 (2021): Comorbid States (1) |
Drug‑induced hemolytic anemia |
Abstract
PDF (Rus)
|
|
O. D. Ostroumova, S. A. Bliznyuk, A. I. Kochetkov, A. G. Komarova |
| |
| No 1 (2021): Comorbid States (1) |
Aspects of practical application of ‘STOPP/START’ criteria in elderly patients with atrial fibrillation and chronic kidney disease in therapeutic department of multi‑speciality hospital |
Abstract
PDF (Rus)
|
|
S. V. Batyukina, O. D. Ostroumova, A. I. Kochetkov, E. Yu. Ebzeeva, R. R. Romanovsky, N. A. Shatalova, M. S. Chernyaeva, D. A. Sychev |
| |
| No 1 (2021): Comorbid States (1) |
Prevalence of comorbidity in chronic HCV‑infection |
Abstract
PDF (Rus)
|
|
E. V. Esaulenko, K. E. Novak, V. V. Basina, A. A. Dzemova, R. A. Ganchenko |
| |
| No 1 (2021): Comorbid States (1) |
Modern view on chronic heart failure therapy: guidelines‑2020 key messages and adjuvant therapy |
Abstract
PDF (Rus)
|
|
A. I. Kochetkov, O. D. Ostroumova, A. V. Arablinsky, G. P. Kovaleva |
| |
| No 1 (2021): Comorbid States (1) |
Possibilities of using fosinopril in treatment of patients with chronic kidney disease in combination with cardiovascular diseases and diabetes mellitus |
Abstract
PDF (Rus)
|
|
E. Yu. Ebzeeva, O. D. Ostroumova, S. V. Batyukina, N. A. Shatalova, N. M. Doldo, R. R. Romanovsky |
| |
| 1 - 8 of 8 Items |
|
